

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



匯聚科技有限公司
TIME Interconnect Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1729)

**APPOINTMENT OF EXECUTIVE DIRECTORS AND
INDEPENDENT NON-EXECUTIVE DIRECTOR**

This announcement is made pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Director(s)**”) of Time Interconnect Technology Limited (the “**Company**”) is pleased to announce that Mr. Chaung Kwai Wing (“**Mr. Chaung**”) and Mr. Hung Wai Lai William (“**Mr. Hung**”) have been appointed as executive Directors; and Dr. Wu Che Yuen Justin (“**Dr. Wu**”) has been appointed as an independent non-executive Director with effect from 1 February 2026.

APPOINTMENT OF EXECUTIVE DIRECTORS

The biographical details of Mr. Chaung are set out below:

Mr. Chaung, aged 62, has over 38 years of experience in the electronics and cable industry, taking senior positions in sales and marketing and general management. Mr. Chaung joined the Company and its subsidiaries (the “**Group**”) in 2020 and is currently the Chief Operating Officer of the Group and acts as director for several subsidiaries of the Group. Mr. Chaung first joined Linkz Industries Limited in 1996 and was transferred to LTK International Limited following the disposal of Linkz’s electronic cables business in 2007. He re-joined the Group in 2020.

Mr. Chaung holds a Master of Business Administration degree and a Bachelor of Science degree from The Chinese University of Hong Kong (“**CUHK**”).

Mr. Chaung has entered into a service contract with the Company, pursuant to which Mr. Chaung agreed to act as an executive Director for a term of 3 years commencing from 1 February 2026. Mr. Chaung shall hold the office until the first annual general meeting of the

Company after his appointment and shall then be eligible for re-election at that meeting pursuant to the articles of association of the Company. Mr. Chaung is entitled to an emolument of HK\$1,822,200 per annum, and such other remuneration and discretionary bonus as may be determined by the Board based on the recommendation of the remuneration committee of the Company (the “**Remuneration Committee**”), with reference to, among other things, the policy and performance of the Company, his qualification, experience, responsibilities and prevailing market conditions.

As at the date of this announcement, Mr. Chaung held a long position of 1,466,000 shares of the Company (the “**Shares**”) representing 0.07% of the total issued Shares and 3,400,000 underlying shares pursuant to share options granted to him by the Company within the meaning of Part XV of the SFO. The share options were granted to Mr. Chaung by the Company pursuant to the share option scheme of the Company.

Save as disclosed above and as at the date of this announcement, Mr. Chaung (i) does not hold any other positions with the Company or any other members of the Group, nor other major appointment and professional qualifications; (ii) did not hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (iii) does not have any interest in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iv) does not have any relationships with any Directors, senior management, substantial shareholders, or controlling shareholders of the Company as defined in the Listing Rules.

Save as disclosed above, there is no other information that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

The biographical details of Mr. Hung are set out below:

Mr. Hung, aged 30, joined the Group in July 2024 and is the Executive Vice President – MedTech of the Group. Mr. Hung is responsible for identifying and evaluating potential overseas investment opportunities to drive the Group’s medical device business, enhancing the research and development and production capabilities of the Group in this sector.

Mr. Hung began his career in 2019 as Management Trainee at Lee Kum Kee International Holdings Limited and subsequently developed his expertise in account management, marketing, and business development.

Mr. Hung obtained a Bachelor of Science degree from Queen Mary University of London. Mr. Hung has been a fellow member of the Institute of Financial Accountants (UK) since December 2020. He is also an International Affiliate Member of the Hong Kong Institute of Certified Public Accountants.

Mr. Hung is now the Executive Committee Member of Hong Kong Electronics Industry Council (HKEIC) and Medical Engineering & Innovation Council (MEIC) under the Federation of Hong Kong Industries (FHKI); an Executive Committee member of The Y. Elites Association; a Member of the Zhuhai Youth Federation; and a Steering Committee Member of CityU HK Industrial and Business Leaders Circle.

Mr. Hung is the son of Mr. Cua Tin Yin Simon, an executive Director and Chief Executive Officer of the Group.

Mr. Hung has entered into a service contract with the Company, pursuant to which Mr. Hung agreed to act as an executive Director for a term of 3 years commencing from 1 February 2026. Mr. Hung shall hold the office until the first annual general meeting of the Company after his appointment and shall then be eligible for re-election at that meeting pursuant to the articles of association of the Company. Mr. Hung is entitled to an emolument of HK\$948,000 per annum, and such other remuneration and discretionary bonus as may be determined by the Board based on the recommendation of the Remuneration Committee, with reference to, among other things, the policy and performance of the Company, his qualification, experience, responsibilities and prevailing market conditions.

Save as disclosed above and as at the date of this announcement, Mr. Hung (i) does not hold any other positions with the Company or any other members of the Group, nor other major appointment and professional qualifications; (ii) did not hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (iii) does not have any interest in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iv) does not have any relationships with any Directors, senior management, substantial shareholders, or controlling shareholders of the Company as defined in the Listing Rules.

Save as disclosed above, there is no other information that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The biographical details of Dr. Wu are set out below:

Dr. Wu, aged 56, is the Associate Dean (Health Systems) of Faculty of Medicine, CUHK. He is responsible for developing a collaborative ecosystem of private healthcare, medical tech industry in Greater Bay Area and beyond.

Dr. Wu is an international leader of digestive diseases. He is currently the President of Asian Pacific Digestive Week Federation, and the Past President of Asian Pacific Association of Gastroenterology and Hong Kong Society of Gastroenterology. He is an eminent medical

educator honoured with 8 education awards for his dedication to nurturing future-ready doctors. He founded Asia's first "Global Physician-Leadership Stream" (GPS) in CUHK, which has been the top undergraduate programme in Hong Kong for over 10 years.

Dr. Wu is also the founding director of Hong Kong Institute of Integrative Medicine in CUHK, pioneering the cooperation between Western and Chinese medicine in the healthcare system. He steered the development of the world's first English Massive Open Online Course (MOOC) on Chinese medicine in collaboration with Coursera. He is serving as board member and chairman of Clinical Governance Committee, a member of the Audit and Risk Committee and a member of the Finance Committee of The Chinese Medicine Hospital of Hong Kong.

Dr. Wu is serving as advisor and investor of biomedical technology companies. He is serving as an independent non-executive director in Aptorum Ltd, a Nasdaq-listed biomedical technology company (Stock code: APM). He is a vice-chairman of Medical Engineering & Innovation Council of Hong Kong Federation of Industries. He also actively contributes to community services, education, and health system development of Greater Bay Area. He is serving in the board of Shaw Prize Foundation, and is a member of Consultative Committee on Guangdong-Hong Kong Co-operation (Guangzhou Nansha).

Dr. Wu obtained a Doctor of Medicine degree, a Master of Business Administration degree and a Bachelor in Medicine and Bachelor of surgery degree from CUHK. Dr. Wu is also a fellow of the Hong Kong Academy of Medicine in the specialty of Gastroenterology & Hepatology.

Dr. Wu has entered into a letter of appointment with the Company, pursuant to which Dr. Wu agreed to act as an independent non-executive Director for a term of 3 years commencing from 1 February 2026. Dr. Wu shall hold the office until the first annual general meeting of the Company after his appointment and shall then be eligible for re-election at that meeting pursuant to the articles of association of the Company. Dr. Wu is entitled to a director's fee of HK\$300,000 per annum, which was determined by the Board based on the recommendation of the Remuneration Committee with reference to, among other things, his qualifications, experience, responsibilities and prevailing market conditions.

As at the date of this announcement, Dr. Wu held a long position of 94,000 Shares, representing 0.005% of the total issued Shares.

Save as disclosed above and as at the date of this announcement, Dr. Wu (i) does not hold any other positions with the Company or any other members of the Group, nor other major appointment and professional qualifications; (ii) did not hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (iii) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iv) does not have any relationships with any Directors, senior management, substantial shareholders, or controlling shareholders of the Company as defined in the Listing Rules.

Dr. Wu has confirmed that (i) he is independent as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, there is no other information that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its warmest welcome to Mr. Chaung, Mr. Hung and Dr. Wu on their new appointment.

By order of the Board
Time Interconnect Technology Limited
Cua Tin Yin Simon
Executive Director and Chief Executive Officer

Hong Kong, 30 January 2026

As at the date of this announcement, the Board comprises two executive Directors, namely Mr. Cua Tin Yin Simon and Mr. Wong Chi Kuen, one non-executive Director, namely Ms. Wang Laichun and four independent non-executive Directors, namely Mr. Ho Hin Shun, Mr. Luk Wai Shing, Mr. Chan Chung Shun Eric and Ms. Chan Kit Fun Fanny.